Barclays Increases AstraZeneca (LON:AZN) Price Target to GBX 9,300
AstraZeneca (LON:AZN) had its price objective boosted by Barclays from GBX 9,200 ($113.22) to GBX 9,300 ($114.45) in a report published on Wednesday morning, Borsen Zeitung reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.
Several other research analysts have also weighed in on the company. Shore Capital reiterated a buy rating on shares of AstraZeneca in a research report on Monday, July 27th. UBS Group reiterated a sell rating on shares of AstraZeneca in a research report on Monday, July 27th. Jefferies Financial Group reiterated a hold rating on shares of AstraZeneca in a research report on Thursday, July 9th. Bryan, Garnier & Co increased their price objective on AstraZeneca from GBX 8,780 ($108.05) to GBX 9,100 ($111.99) and gave the stock a buy rating in a research report on Tuesday, June 2nd. Finally, DZ Bank increased their price objective on AstraZeneca from GBX 6,500 ($79.99) to GBX 7,300 ($89.84) and gave the stock a sell rating in a research report on Friday, May 1st. Six analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of GBX 8,347.78 ($102.73).
AZN stock opened at GBX 8,530 ($104.97) on Wednesday. The company has a debt-to-equity ratio of 171.72, a current ratio of 0.75 and a quick ratio of 0.56. The business has a 50 day simple moving average of GBX 8,583.32 and a 200-day simple moving average of GBX 7,938.56. The firm has a market capitalization of $111.94 billion and a PE ratio of 73.73. AstraZeneca has a 1 year low of GBX 83.80 ($1.03) and a 1 year high of GBX 9,537.09 ($117.37).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Are all No-Load Funds Equal?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.